

05/12/2022

Antivenin Procedure Code J0841 (ANAVIP®) to Become a Medicaid Benefit Effective June 1, 2022

Background:

On January 5, 2022, HHSC received an inquiry from an MCO regarding Texas Medicaid's coverage for the antivenom, CROFAB®. HHSC staff determined that CROFAB®, while previously covered, was made not a benefit on September 30, 2017, after its rebate had expired. Through further research, HHSC staff identified an alternative antivenom used to treat the same snake bites, ANAVIP®, which does have an active rebate.

Key Details:

ANAVIP® is an antivenom indicated for the management of adult and pediatric patients with North American Pit Viper envenomation. It received initial U.S. Food and Drug Administration (FDA) approval in 2015 and coverage was extended for three additional North American snake species in 2021.

Effective for dates of service on or after June 1, 2022, antivenin procedure code J0841 (ANAVIP®) will become a benefit of Texas Medicaid.

Procedure code J0841 may be reimbursed for the following places of service and provider types:

Place of Service	Provider Type
Office	Physician assistants, nurse practitioners, clinical nurse specialists, and physicians
Outpatient hospital	Hospital providers